Eliquis (apixaban) is part of a group of medications called direct oral anticoagulants (DOACs). It works by blocking Factor Xa, an enzyme that helps your blood clot. Compared to older drugs like warfarin, Eliquis doesn’t require constant blood tests or strict dietary rules.
It is a commonly prescribed blood thinner used for conditions like atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism. If you’re taking it, you might wonder how long it stays in your system. To understand this, you first need to know what Eliquis’ half-life is.
What Does “Half-Life” Mean?
The half-life of a drug is how long it takes for half of it to leave your bloodstream. While the amount of drug being removed gets smaller each time, the time it takes for the drug level to drop by half stays the same.
The concept of a drug’s half-life is especially important because it helps doctors determine how often you need to take your meds to keep them working properly. Things like how your body processes and eliminates the drug can also influence its half-life.
Usually, after about 4 half-lives, there’s so little of the drug left (only about 6.25% of the original amount) that it doesn’t have any noticeable effect anymore.
What is the Half-Life of Eliquis?
Eliquis has a half-life of about 12 hours in healthy adults. This means that every 12 hours, the amount of Eliquis in your bloodstream drops by half. Even though the drug’s concentration decreases, its effects last longer, which is why you only need to take it twice a day to keep your blood thin consistently.
If you have certain conditions, like kidney problems, the half-life might be a bit longer. That’s because about 27% of Eliquis is cleared out through your kidneys, and if they’re not working as well, the drug sticks around longer. Your doctor might check your kidney function to decide the right dose for you.
Why Does the Half-Life of Apixaban Matter?

The half-life of apixaban affects how it’s used:
-
- Dosing: Because the drug’s effect starts to wear off after about 12 hours, Eliquis needs to be taken twice a day to keep your blood thin enough to prevent clots without increasing the risk of bleeding.
-
- Drug Toxicity: This can happen if someone takes too much of a drug, is accidentally given the wrong dose, or has health problems like kidney or liver disease that prevent the body from clearing the drug properly. Toxicity can develop gradually because it takes about 5 to 6 half-lives for drugs taken regularly to build up to a stable level in the body.
-
- Before Surgery: If you need surgery or a procedure, you’ll likely have to stop Eliquis temporarily to avoid bleeding complications. The half-life helps doctors figure out how far in advance you should stop taking it, often 24 to 48 hours beforehand.
What Can Affect the Half-Life of Eliquis?

Several things can make Eliquis last longer or shorter in your body:
1. Drug Interactions
Eliquis is broken down in the body by proteins called CYP3A4 and P-gp. Certain drugs can either increase or decrease how much Eliquis is in your system, which can affect its safety and effectiveness.
-
- Inhibitors (e.g., ketoconazole, ritonavir): These drugs block CYP3A4 and P-gp, causing more Eliquis to stay in your body. This increases the risk of bleeding. According to Eliquis’ prescribing information, if you’re taking 5 mg or 10 mg of Eliquis twice a day, your dose should be decreased by 50%. If you’re on 2.5 mg twice a day, avoid these drugs entirely. (Note: Clarithromycin, another inhibitor, doesn’t require a dose change when taken with Eliquis.)
-
- Inducers (e.g., rifampin, carbamazepine, St. John’s wort): These drugs speed up how quickly Eliquis is broken down, lowering its levels in your body. This increases the risk of stroke or blood clots. Avoid taking these drugs with Eliquis.
Always let your doctor know about all medications, supplements, or herbs you’re taking to avoid potential risks.
2. Age
Aging results in several significant changes in the human body, including altered liver function, slower digestion, and increased body fat. These changes are further influenced by comorbid diseases, weakness, concomitant medications, and genetics. Together, they have the potential to alter drug clearance.
3. Kidney Function
If your serum creatinine (a marker of kidney function) is 1.5 mg/dL or higher, and you either weigh 132 lbs or less or are 80 years or older, your Eliquis dose is reduced to 2.5 mg twice daily. Eliquis has not been fully studied in people with end-stage kidney disease (ESRD) or those on dialysis.
4. Liver Function
The liver’s ability to clear drugs affects how much of the medicine and its byproducts stay in the body. This can significantly impact how well the medicine works and the likelihood of risk or side effects. Since approximately 75% of Eliquis is broken down in the liver, problems here can also change its half-life.
5. Body Weight
Drugs that dissolve more easily in lipids (fats, oils, or waxes) than in water (lipophilic drugs) may stay in the fat tissue longer, potentially increasing the drug’s half-life. Most DOACs are reported to be moderately lipophilic, while Pradaxa (dabigatran) is considered highly lipophilic.
Comparing Eliquis’ Half-Life to Other Anticoagulants
Here’s how Eliquis stacks up against other anticoagulants when it comes to elimination:
| DOACs | Half-life (hours) | Renal Elimination (%) | Hepatic Elimination | Lipophilicity |
|---|---|---|---|---|
| Eliquis (Apixaban) | 12 | 27 | Majority | Moderate |
| Pradaxa (Dabigatran) | 12-14 | 80 | Minimal | High |
| Xarelto (Rivaroxaban) | 5-9 (healthy adults) / 11-13 (elderly) | 35 | Moderate | Moderate |
| Savaysa (Edoxaban) | 10-14 | 50 | Moderate | Moderate |
Wrapping Up
The half-life of Eliquis is an essential factor in determining how it works and how it’s prescribed. With a 12-hour half-life, it’s taken twice a day to maintain consistent blood thinning. Factors like kidney function, liver health, body weight, and drug interactions can influence how long Eliquis stays in your system and how effective it is.
It’s important to follow your doctor’s dosing instructions closely. If you have any concerns or questions about Eliquis, talk to your doctor to ensure it’s the right fit for your needs.
Frequently Asked Questions
Related Articles
Sources
Borst, J. M., Van Rein, N., Bakker, E. C. M. D., Vukadin, N., Rier, M., Mairuhu, A. T. A., Hudig, F., Bosma, L. B. E., Wilms, E. B., & Visser, L. E. (2020). Body weight is negatively associated with direct oral anticoagulant trough concentrations in dabigatran and apixaban users. British Journal of Haematology, 191(5), 941–944. https://doi.org/10.1111/bjh.17009
Maanen, A. C. D., Wilting, I., & Jansen, P. a. F. (2019). Prescribing medicines to older people—How to consider the impact of ageing on human organ and body functions. British Journal of Clinical Pharmacology, 86(10), 1921–1930. https://doi.org/10.1111/bcp.14094
McLachlan, A. J., & Pont, L. G. (2011). Drug Metabolism in Older People–A key consideration in achieving Optimal outcomes with Medicines. The Journals of Gerontology Series A, 67A(2), 175–180. https://doi.org/10.1093/gerona/glr118
Frost, C., Wang, J., Nepal, S., Schuster, A., Barrett, Y. C., Mosqueda-Garcia, R., Reeves, R. A., & LaCreta, F. (2013). Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. British journal of clinical pharmacology, 75(2), 476–487. https://doi.org/10.1111/j.1365-2125.2012.04369.x
Thomas, A., Fang, M. C., Kogan, S., Hubbard, C. C., Friedman, P. N., Gong, L., Klein, T. E., Nutescu, E. A., O’Brien, T. J., Tuck, M., Perera, M. A., & Schwartz, J. B. (2022). Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation. JACC. Advances, 1(2), 100039. https://doi.org/10.1016/j.jacadv.2022.100039
Hallare, J., & Gerriets, V. (2023, June 20). Half life. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK554498/
Bristol-Myers Squibb Company. (2021). Highlights Of Prescribing Information Of Eliquis. Retrieved from https://packageinserts.bms.com/pi/pi_eliquis.pdf
Agrawal, A., Kerndt, C. C., & Manna, B. (2024, February 22). Apixaban. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK507910/
Hurst, K. V., O’Callaghan, J. M., & Handa, A. (2017). Quick reference guide to apixaban. Vascular health and risk management, 13, 263–267. https://doi.org/10.2147/VHRM.S121944





